ClinicalTrials.gg
Not yet recruitingNCT07944729VR-AUTISM-NURSUpdated Nov 18, 2026

Virtual Reality-Supported Autism Education for Nursing Students

An interventional study of VR-Supported Autism Education Program in Autism Spectrum Disorder and Nursing Education, sponsored by Kirsehir Ahi Evran Universitesi. Not yet recruiting. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-18.

Sponsored by Kirsehir Ahi Evran Universitesi · Not applicable, Interventional, and Other

Updated Nov 18, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
80
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The goal of this clinical trial is to learn if a virtual reality (VR)-supported autism education program improves knowledge, awareness, and attitudes about autism spectrum disorder (ASD) in fourth-year nursing students. The main questions it aims to answer are:

  • Does the program increase nursing students' knowledge of autism?
  • Does the program increase their awareness of autism and improve their attitudes toward people with autism?

Researchers will compare students who take the program with students who receive no education during the study, to see if the program improves knowledge, awareness, and attitudes, and whether these effects last one month after the program.

Participants will:

  • Attend one 90-minute face-to-face session per week for 8 weeks (education group only). Sessions in weeks 1 to 7 use active learning methods such as group work and brainstorming. In week 8, each student watches a short (about 5-minute) 360-degree VR scenario that shows a hospital visit from the point of view of a child with autism, followed by a guided group discussion.
  • Complete questionnaires on autism knowledge, awareness, and attitudes before the program, after the program (week 8), and one month later.

Students in the control group will be offered the same program after the study ends.

Read the detailed description

Background: Nurses working in primary care and child health services are in a key position to recognize early signs of autism spectrum disorder (ASD) and to refer children for timely assessment. However, nursing students often report limited knowledge and low confidence in this area. Immersive virtual reality (VR) allows learners to experience sensory and social situations from the perspective of a child with autism without involving children in the teaching process.

Design: This is a single-center, two-arm, parallel-group, open-label randomized controlled trial with pretest, posttest, and one-month follow-up measurements. The study will be reported according to CONSORT and the CONSORT-Outcomes 2025 extension.

Randomization: After baseline measurement, participants will be allocated 1:1 by simple randomization using a computer-generated sequence (randomizer.org). Randomization will be performed by an independent researcher not involved in delivering the intervention, and the allocation list will be concealed from the research team until assignment is complete. Data will be coded by group (Group A/Group B) and analyzed by a statistician blinded to group allocation.

Intervention content: Weekly modules cover the diagnostic framework of ASD, social communication and interaction, restricted and repetitive behaviors, sensory experience and perspective taking, comorbidities and differential diagnosis, the nurse's role in early identification and referral, and stigma and professional attitudes. Teaching methods include station rotation, six thinking hats, brainstorming, the six-shoe technique, and cooperative learning (inner-outer circle). Week 8 is a simulation session ("A Journey into the World of a Child with Autism") in which students experience an 8-year-old child's hospital visit first in an unadapted and then in an autism-friendly environment, followed by a structured debriefing. Content will be reviewed by autism experts and piloted with nursing students before the trial.

Statistical analysis: Group-by-time effects across the three measurements will be analyzed with two-way repeated-measures ANOVA, or the nonparametric F1-LD-F1 model if assumptions are not met. Analyses will follow the intention-to-treat principle, and missing data will be handled by multiple imputation. Effect sizes (Cohen's d, partial eta squared) will be reported. The significance level is p\<0.05.

02

Conditions studied

  • Autism Spectrum Disorder
  • Nursing Education

Keywords

  • Virtual Reality
  • Nursing Students
  • Autism Awareness
  • Attitude
  • Simulation Training
  • Early Diagnosis
03

In context

Autism Spectrum Disorder

1,732 studies on the registry are indexed under Autism Spectrum Disorder; 504 are open to participants now.

This study's planned enrollment of 80 is above the median of 52 across 1,373 interventional studies indexed under Autism Spectrum Disorder.

Browse Autism Spectrum Disorder studies →

Lead sponsor

Kirsehir Ahi Evran Universitesi is the lead sponsor of 142 studies on the registry; 55 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Fourth-year student in the Department of Nursing, Faculty of Health Sciences, Kirsehir Ahi Evran University
  • Has completed the pediatric (child health and diseases) nursing course
  • Has not previously attended a structured education program on autism spectrum disorder
  • Agrees to participate voluntarily and signs the form
  • Is able to attend the education sessions and measurements

Exclusion criteria

Exclusion Criteria:

  • Known health condition that may prevent the use of virtual reality (e.g., severe motion sickness or vertigo, epilepsy)
  • Not completing the baseline (pretest) measurements
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
80 participants (estimated)

Study arms

  • Experimental
    VR-Supported Autism Education

    Participants will attend an 8-week modular autism education program with one 90-minute face-to-face session per week. Weeks 1-7 consist of active learning modules on autism spectrum disorder. Week 8 consists of a virtual reality simulation session followed by a structured debriefing.

    Behavioral: VR-Supported Autism Education Program

  • No intervention
    Control

    Participants will receive no education during the study period and will complete the same questionnaires at the same time points (baseline, week 8, and week 12). They will be offered the same education program after the follow-up measurement.

Interventions

  • BehavioralVR-Supported Autism Education Program

    An 8-week program with one 90-minute face-to-face session per week. Weeks 1-7 cover the diagnostic framework of autism spectrum disorder, social communication and interaction, restricted and repetitive behaviors, sensory experience and perspective taking, comorbidities and differential diagnosis, the nurse's role in early identification and referral, and stigma and professional attitudes, using station rotation, six thinking hats, brainstorming, six-shoe technique, and cooperative learning methods. In week 8, each student experiences an approximately 5-minute immersive 360-degree VR scenario of an 8-year-old child's hospital visit from the child's perspective, first in an unadapted and then in an autism-friendly environment, followed by a structured debriefing.

06

What researchers measure

Primary outcomes

  1. Autism Knowledge Score (Knowledge about Childhood Autism among Health Workers Questionnaire)

    Autism knowledge will be measured with the Turkish version of the Knowledge about Childhood Autism among Health Workers (KCAHW) Questionnaire. It has 19 items covering social interaction, communication, behavioral patterns, and features of the disorder. Each correct answer scores 1 and each incorrect or "don't know" answer scores 0, giving a total score of 0 to 19. Higher scores indicate greater knowledge of childhood autism.

    Time frame: Baseline (before the intervention), week 8 (immediately after the intervention), and week 12 (one month after the intervention)

Secondary outcomes

  1. Autism Awareness Score (Autism Awareness Scale)

    Autism awareness will be measured with the Autism Awareness Scale, which has 32 items in 7 subscales (restricted interests and repetitive behaviors, social interaction and communication, causes of autism, peer relationships, key elements of intervention, physical characteristics, and early warning signs). Items are rated on a 5-point Likert scale (1 = strongly disagree, 5 = strongly agree), with reverse-scored items, giving a total score of 32 to 160. Higher scores indicate greater awareness of autism.

    Time frame: Baseline (before the intervention), week 8 (immediately after the intervention), and week 12 (one month after the intervention)

  2. Attitudes Toward Autism Score (Societal Attitudes Towards Autism Scale)

    Attitudes toward autism will be measured with the Turkish version of the Societal Attitudes Towards Autism (SATA) Scale, which has 26 items in 3 subscales (personal distance, knowledge, and social life). Items are rated on a 4-point scale, with reverse-scored items, giving a total score of 26 to 104. Higher scores indicate more positive attitudes toward individuals with autism.

    Time frame: Baseline (before the intervention), week 8 (immediately after the intervention), and week 12 (one month after the intervention)

07

Study locations

No study locations are listed for this record.

08

References and documents

Publications

  • Flood LN, Bulgrin A, Morgan BL. Piecing together the puzzle: development of the Societal Attitudes towards Autism (SATA) scale. Journal of Research in Special Educational Needs. 2013;13(2):121-128.
  • Batum S, Aydin A. Turkish adaptation of the Societal Attitudes Towards Autism Spectrum Disorder Scale. Dumlupinar University Journal of Institute of Educational Sciences. 2021;5(2):1-24.
  • Yazici MS, Karsantik I. Development of the Autism Awareness Scale: a validity and reliability study. Marmara University Ataturk Faculty of Education Journal of Educational Sciences. 2023;58:18-40. doi: 10.15285/maruaebd.1189906
  • Gurbuz-Ozgur B, Aksu H, Eser E. Validity and reliability of the Turkish version of the knowledge about childhood autism among health workers questionnaire. Psychiatry and Clinical Psychopharmacology. 2019. doi: 10.1080/24750573.2019.1637326
  • Bakare MO, Ebigbo PO, Agomoh AO, Menkiti NC. Knowledge about childhood autism among health workers (KCAHW) questionnaire: description, reliability and internal consistency. Clin Pract Epidemiol Ment Health. 2008 Jun 6;4:17. doi: 10.1186/1745-0179-4-17. PubMed 18538020 ↗
  • Gurbuz Ozgur B, Aksu H, Eser E. Effectiveness of an autism spectrum disorder screening and follow-up training program for primary health care professionals in Turkiye. Turk J Pediatr. 2025 Oct 6;67(5):623-633. doi: 10.24953/turkjpediatr.2025.6322. PubMed 41327987 ↗

Individual participant data

Plan to share: No — Individual participant data will not be shared publicly because participants were informed in the consent process that their data would be used only by the research team for scientific purposes. Aggregate results will be published in a peer-reviewed journal. De-identified data may be made available by the principal investigator upon reasonable request after publication, subject to ethics committee approval.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Nov 2026; primary completion for Jan 2027, 1 month later.

Of 805 non-industry interventional studies with no phase under Autism Spectrum Disorder, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 48. This study's planned 1 month is below that.

Counting every sponsor, half of 828 studies reached it within 25 months; a quarter within 12 and three quarters within 47.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 12, 2026
First posted
Nov 18, 2026
StartEst.
Nov 17, 2026
Primary completionEst.
Jan 15, 2027
CompletionEst.
Feb 28, 2027
Last update
Nov 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 18, 2026
Show all 1 update
  1. Nov 18, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07944729
Responsible party
Edanur Tar Bolacali (Asst. Prof., Kirsehir Ahi Evran Universitesi) — Principal investigator
First posted
Nov 18, 2026
Start date
Nov 17, 2026 (estimated)
Primary completion
Jan 15, 2027 (estimated)
Completion
Feb 28, 2027 (estimated)
Last update
Nov 18, 2026

Study contacts

Edanur Tar Bolacalı, PhD
Contact
edanurtar.1107@gmail.com
05332668360

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion